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Atrial fibrillation (AF) is the most common arrhythmia of the heart, affecting 2-3% of the 
population. AF decreases the quality of life and increases the risk of mortality in patients. Although 
many patients see improvement with available treatments, a significant number do not. This 
necessitates further study into mechanisms of AF to elucidate new therapeutic targets. Many 
arrhythmias arise from the dysfunction of calcium handling within cardiomyocytes. The contraction 
of cardiomyocytes relies on the regulated release of calcium from the sarcoplasmic reticulum (SR), via 
the ryanodine receptor (RyR2). In many arrhythmias, RyR2 becomes “leaky” and spontaneously 
releases calcium in a process called store overload- induced calcium release (SOICR). This can lead to 
the development of delayed afterdepolarisations and trigger arrhythmic contractions. The function of 
RyR2 can be modulated by many accessory proteins, including calsequestrin 2 (CSQ2). CSQ2 primarily 
buffers Ca2+ within the SR, but can also influence RyR2’s propensity for SOICR. Both human and 
animal studies indicate a relative increase of RyR2, and/or a relative decrease of CSQ2 (increased 
RyR2:CSQ2) can result in an arrhythmic phenotype.  
My project aimed to investigate the functional effects of changing RyR2:CSQ2 on the 
propensity for SOICR by co-expressing RyR2 and CSQ2 within HEK293 cells, by using fluorescently 
tagged RyR2 and CSQ2. HEK293 cells were loaded with a Ca2+-dye and underwent single-cell calcium 
imaging with increasing [Ca2+]O (0.1-1 mM) to determine the effect of changing RyR2:CSQ2 on the 
propensity for SOICR. The results of this show a biphasic effect of decreasing RyR2:CSQ2 on the 
propensity for SOICR, where high RyR2:CSQ2 cells had a higher frequency of SOICR events than 
the CSQ2-null cells (p=0.0326), and the medium RyR2:CSQ2 cells (p=0.0008), and low RyR2:CSQ2 
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cells (p<0.0001). These findings indicate that a high RyR2:CSQ2 ratio increases RyR2’s propensity for 
SOICR more than a complete loss of CSQ2. Despite this, my finding of decreased RyR2:CSQ2 being 
protective against SOICR also provides hope for future novel therapeutics that can restore the balance 
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1.1 Cardiovascular System and Atrial Fibrillation 
The cardiovascular system consists of the heart and the blood vessels that supply the organs 
of the body. The heart functions to pump blood through the blood vessels by rhythmically contracting, 
thereby transporting vital nutrients, gases, and hormones around the body. To perform these 
functions, the heart must have a regular rhythm and optimal contraction for the present demand, 
being able to adapt to exercise and stress by increasing the rhythm (heart rate). Diseases that affect 
this rhythm of the heart are called arrhythmias, the most common of which being atrial fibrillation 
(AF) (Ball, Carrington et al. 2013). 
1.1.1 Atrial Fibrillation 
Atrial fibrillation is a supraventricular tachyarrhythmia observed as an uncoordinated 
contraction of the atria and ventricles (European Heart Rhythm, Heart Rhythm et al. 2006). AF is 
typically diagnosed by abnormal electrocardiograms (ECGs) that show the replacement of the p-wave 
with repetitive oscillatory wavelets (Haissaguerre, Jais et al. 1998, European Heart Rhythm, Heart 
Rhythm et al. 2006). AF is characterized as a rapid and irregular beating of the atria of the heart, often 
being described as “irregularly irregular” pulse due to both an increased and inconsistent heart rate. 
This is due the normal electrical impulses of the sinoatrial node becoming overwhelmed by irregular 
ectopic impulses from focal points near the pulmonary veins on the left atrium (Haissaguerre, Jais et 
al. 1998) often being seen as wavelets (Haissaguerre, Jais et al. 1998). Wavelets generated from these 
non-sinus action potentials (APs) are then able to propagate around anatomical obstacles to re-enter 
the atria, leading to the fibrillation pattern seen on ECG that AF is known for (Haissaguerre, Jais et 
al. 1998). The uncoordinated contraction between the atria and ventricles in AF will lead to a loss of 
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mechanical function and affect the function of the heart (European Heart Rhythm, Heart Rhythm et 
al. 2006).   
1.1.2 Epidemiology of Atrial Fibrillation in New Zealand 
AF is seen to affect 2-3 % of the population in western countries (Ball, Carrington et al. 2013), 
with this number expected to rise in coming decades as populations age (Schnabel, Yin et al. 2015) 
and detection methods improve (Zungsontiporn and Link 2018). In New Zealand specifically, it has 
also been seen that AF has a higher prevalence in Māori and Pacific communities (Gu, Doughty et al. 
2018).  
 Individuals with AF are associated with increased morbidity and decreased quality of life. Due 
to depressed contractility, individuals with AF will have significant difficulty with exercise and other 
strenuous activity (Belus, Piroddi et al. 2010, Krisai, Blum et al. 2020). The increased mortality seen in 
AF is primarily due to an association of increased stroke risk (Pathak, Middeldorp et al. 2014, 
Zimetbaum 2017, Krisai, Aeschbacher et al. 2020). This is due to the decreased contractility during an 
AF event which can lead to stasis of blood within the left atrial appendage which can then coagulate 
and create a significant thromboembolic risk (European Heart Rhythm, Heart Rhythm et al. 2006). 
The consequences of AF are compounded by a significant number of AF patients showing 
unresponsiveness to current treatments (Pathak, Middeldorp et al. 2014). 
1.1.3 Classification and Progression of Atrial Fibrillation 
AF is typically split into different classifications relating to the duration and severity of the 
events as defined by the ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial 
Fibrillation (European Heart Rhythm, Heart Rhythm et al. 2006). Paroxysmal AF describes episodes 
that occur suddenly,, and generally do not last more than 7 days, with most events terminating in 48 
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hours. Persistent AF refers to episodes that last longer than 7 days, and typically require intervention 
to terminate (such as cardioversion) (Bhatt and Fischer 2015). The most severe form of AF without 
termination is described as permanent AF, and does not respond to cardioversion (Bhatt and Fischer 
2015). Although milder forms of AF can be near asymptomatic, progression to more serious 
classifications of AF has been documented both clinically and experimentally (Wijffels, Kirchhof et 
al. 1995, Bhatt and Fischer 2015, Krisai, Aeschbacher et al. 2020). The progression of mild AF to 
more serious forms seems to be linked to remodelling of the atria, both structurally and electrically 
(Dobrev 2006, Nattel, Burstein et al. 2008). 
1.1.4  Pathophysiology of Atrial Fibrillation 
Although there are a few theories for the pathophysiology that causes AF (Pogwizd and Bers 
2004), it is thought that AF is prominently linked to dysfunctional calcium handling within individual 
cardiomyocytes (Yeh, Wakili et al. 2008, Voigt, Li et al. 2012, Voigt, Heijman et al. 2014). This 
abnormal calcium handling is believed to lead to the generation of non-sinus APs from around the 
pulmonary veins. These non-sinus APs are what is thought to initiate the re-entry activity that is more 
commonly associated with AF (Pogwizd and Bers 2004, Dobrev and Wehrens 2017). Abnormal 
calcium handling is also thought to contribute to the maintenance of this re-entrant activity (Dobrev 
and Wehrens 2017). For this reason, an understanding of the mechanisms that trigger the abnormal 
calcium handling of individual myocytes may be of benefit in understanding the disease as a whole. 
1.2  Calcium Handling of the Heart 
For the heart to contract effectively, APs generated in the sinoatrial node must be translated 
into contraction of individual myocytes. The intracellular messenger that is critical in this transduction 
is calcium ions (Ca2+). Ca2+ is involved in both the amplification of the signal (the AP) within the cell, 
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and the initiation of contraction of the myofilaments. The process of translating the APs into 
contraction is called excitation-contraction coupling (EC Coupling) where the electrical impulses that 
propagate through the heart are coupled to the contraction of the cardiomyocytes (Bers 2002).  
1.2.1 Excitation-Contraction Coupling 
EC coupling is a process that encompasses many sequential events that occur within a typical 
heartbeat (Fig. 1.1). This refers to the release of Ca2+ from the intracellular store of the myocyte called 
the sarcoplasmic reticulum (SR). EC coupling is initiated by the cardiomyocyte becoming depolarized 
during an action potential (by various voltage gated Na+ channels). This depolarization then allows 
voltage-gated Ca2+ channels such as the L-type calcium channel (LTCC) to open. Ca2+ can then enter 
the cell via LTCC and cross the dyad (the small cytosolic region between the SR and invaginations of 
the sacrolemma, the t-tubule). After crossing the dyad, the Ca2+ can bind to the ryanodine receptor 
(RyR2) on the membrane of the SR (Bers 2002). This binding of Ca2+ to RyR2 triggers a particularly 
important process within EC coupling, which is called calcium-induced calcium release (CICR) (Bers 
2002). The binding of Ca2+ to the cytosolic domains of RyR2 causes the opening of the channel, and 
allows the Ca2+ stored within the SR to be released into the cytosol, known as CICR (Bers 2002, Jones, 
Guo et al. 2017). This massively increases the concentration of cytosolic Ca2+ from a diastolic 
concentration to a systolic concentration (Bers 2002). With a high enough Ca2+ concentration, Ca2+ 
will bind to elements of the myofilaments to initiate contraction (Bers 2002).  
An equally important aspect to EC coupling is a controlled relaxation of the cardiomyocyte. 
For the cardiomyocyte to relax after a contraction, enough Ca2+ must be removed from the cytosol to 
return to diastolic Ca2+ concentration and the Ca2+ store of the SR must be replenished. The three 
main ways this is achieved are (1.) reuptake into the SR by Sarcoplasm Reticulum Ca2+-ATPase 
(SERCA), (2.) efflux by the sarcolemmal Na+-Ca2+ exchanger (NCX), and (3.) efflux by the 
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sarcolemmal Ca2+-ATPase (Bers 2002). Reuptake by SERCA is the main mechanism of relaxation, 
removing ~70% of the activator Ca2+ in the cytosol (Bers 2002). NCX removes another ~28% of the 
activator Ca2+, leaving around 1% to be removed by sarcolemmal Ca2+-ATPase (Bers 2002). All of 
these processes working together ensure a controlled movement of Ca2+around a cardiomyocyte, and 
allow for controlled and coordinated contraction of the heart.  
 
Figure 1-1 Schematic displaying the difference in movement of calcium between CICR (left) and 
SOICR (right) within the cardiomyocyte. For the left: 1) An action potential from the Sinoatrial node 
travels down the t-tubule. 2) The cell depolarises and causes the opening of LTCC 3) Ca2+ enters and binds 
to RyR2. 4) RyR2 opens and Ca2+ is released from the SR (CICR) and binds to other RyR2. 5) Cytosolic Ca2+ 
concentration increases. 6) Ca2+ binds to myofilaments and triggers contraction. 7) Ca2+ is re-uptaken by 
SERCA (70%) or extruded out of the cell via NCX (30%). For the right: 1) A significant spontaneous Ca2+ leak 
occurs. 2) Loss of effective Ca2+ reuptake into the SR by SERCA leads to an increased reliance on ↑NCX 
activity. 3) ↑NCX activity causes an electrogenic increase in Na+ concentration. 4) The increased positive 
charge inside the cardiomyocytes leads to a DAD and the cell depolarises. This will then cause CICR (left). 




1.2.2 Store Overload-Induced Calcium Release  
The opening of RyR2 is typically achieved by the binding of Ca2+ on the cytosolic side of the 
channel, with this Ca2+ normally arising from influx into the cardiomyocyte via the L-type calcium 
channel (CICR) (Bers 2002). This is not the only condition in which RyR2 can open however, as there 
is another process called store overload-induced calcium release (SOICR) (Fig. 1.2) (Jiang, Xiao et al. 
2004, Dobrev and Wehrens 2017).  
SOICR is a process that can lead to the spontaneous opening of the RyR2 channel, 
independent of cytosolic calcium concentration (Jiang, Xiao et al. 2004). When the concentration of 
Ca2+ within the lumen of the SR reaches a high enough threshold, the RyR2 will open and release the 
SR calcium store contents, independent of Ca2+ binding to its cytosolic domains (as seen in CICR) 
(Jiang, Xiao et al. 2002, Jiang, Xiao et al. 2004, Jones, Guo et al. 2017). We refer to these spontaneous 
Ca2+ releases (SCR) as Ca2+ sparks in a myocyte. These Ca2+ sparks are thought to be the link between 
abnormal Ca2+ cycling and arrhythmia (Yeh, Wakili et al. 2008, Voigt, Heijman et al. 2014).  
The link between SOICR and arrhythmia (such as AF) is via delayed after-depolarisations 
(DADs) (Jiang, Xiao et al. 2004, Voigt, Li et al. 2012, Heijman, Voigt et al. 2014, Voigt, Heijman et al. 
2014). The Ca2+ sparks that are associated with SOICR will not be enough to trigger a whole-cell 
depolarization, but they will of course still raise the cytosolic Ca2+ concentration (Bers 2002). After a 
SOICR event, Ca2+ will need to be removed from the cytosol to restore the diastolic concentration 
for Ca2+. As the RyR2 - and therefore the SR Ca2+ store - has become “leakier” in SOICR, any uptake 
of SOICR-associated Ca2+ by SERCA will simply contribute to more SOICR events. This would 
explain experimental data that shows cells loaded with Ca2+ indicators undergoing SOICR events 
appear to “oscillate”, as Ca2+ uptake by SERCA is spontaneously re-released repeatedly (Jiang, Xiao 
et al. 2004, Handhle, Ormonde et al. 2016, Waddell, Zhang et al. 2016). The decreased effectiveness 
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of SERCA Ca2+ reuptake means that cardiomyocytes must rely on NCX for Ca2+ efflux (and the 
sarcolemmal Ca2+-ATPase to a lesser degree). As NCX is electrogenic during Ca2+ extrusion (3Na+ in 
:1Ca2+ out) (Bers 2002), the cell can depolarize if enough Ca2+ is extruded via NCX, due to an increased 
Na+ concentration within cytosol. This is commonly seen electrically as a DAD following 
repolarization after a normal sinus AP (Fig. 1.1) (Voigt, Li et al. 2012, Heijman, Voigt et al. 2014). As 
the cell has depolarized, it may lead to the development of a DAD-triggered AP (Voigt, Li et al. 2012, 
Heijman, Voigt et al. 2014, Voigt, Heijman et al. 2014). 
 
Figure 1-2 Model showing the mechanism of how changing the threshold of SOICR can lead to 




1.3 Ryanodine Receptor 2 
RyR2 is the isoform of the ryanodine receptor that is present in the cardiomyocyte, with RyR1 
being present in skeletal muscle and RyR3 being more ubiquitously expressed (Fill and Copello 2002). 
Its structure compromises of four identical monomers, each with a large cytosolic domain and a far 
smaller luminal domain (Jones, Guo et al. 2017). It is also the largest ion channel ever observed in 
nature.  
RyR2 is likely the most important channel in the process of CICR, as most of the Ca2+ that is 
involved in contraction of the cardiomyocyte comes from the SR via RyR2 (Bers 2002). This 
importance also makes RyR2 relevant in many pathologies, with it being especially relevant to 
arrhythmia.  
1.3.1 RyR2 and the Threshold for SOICR 
Many factors that influence the activity of RyR2 modify the threshold (luminal concentration 
of Ca2+) at which SOICR can occur. The threshold at which SOICR is likely to occur via RyR2 is not 
consistent between individuals or within individuals at different time points, often being changed 
transiently (Jiang, Xiao et al. 2004). This transient change to the threshold for SOICR has been 
extensively linked to stress induced arrhythmias (Jiang, Xiao et al. 2004, Jiang, Wang et al. 2005, Jiang, 
Jones et al. 2010).  
1.3.2 Phosphorylation of RyR2 
The most widely studied mechanism for altering SOICR likelihood is the phosphorylation of 
RyR2 in stress induced conditions. During exercise or stressful events, a beta-adrenergic response 
occurs where the beta receptors of the heart are activated, leading to the downstream activation of 
kinases. Many of these downstream protein kinases of the beta-receptor have been extensively linked 
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with this catecholamine response, phosphorylating important sites on the RyR2 (Gonano and Jones 
2017). The two most notable of these kinases are protein kinase A (PKA)(Jiang, Wang et al. 2005), 
and Ca2+/Calmodulin-Dependent Protein Kinase II (CaMKII) (Wehrens, Lehnart et al. 2004). The 
phosphorylation of RyR2 by these kinases will increase the amount of Ca2+ released from RyR2 by 
increasing both the open probability (PO) and the duration of opening to have an inotropic effect on 
the heart. Phosphorylation of RyR2 will also increase the risk of SOICR.  In most individuals, the 
phosphorylation of RyR2 will not lead to a significant increase in SOICR events as the leak of Ca2+ 
from the SR will be negligible or even non-existent. In individuals with specific mutations present in 
RyR2, this phosphorylation of RyR2 will be enough to cause a drastic reduction in the threshold for 
SOICR, and therefore lead to a significant increase in SOICR events (Jiang, Xiao et al. 2004, Jiang, 
Wang et al. 2005). This has been well documented in catecholaminergic polymorphic ventricular 
tachycardia (CPVT), with most cases (type I CPVT) being linked to mutations in RyR2 (Laitinen, 
Brown et al. 2001, Jiang, Wang et al. 2005). These mutations cause a gain of function where the RyR2 
becomes more susceptible to SOICR after phosphorylation (Jiang, Xiao et al. 2004, Jiang, Wang et al. 
2005, Jiang, Jones et al. 2010).  
Although phosphorylation may increase the amount of Ca2+ released in SOICR, for SOICR 
to be able to cause DADs a significant amount of Ca2+ will need to leak during a SOICR event. 
Intrinsic mutations of RyR2 combined with phosphorylation of RyR2 discussed above would be 
enough to drasticly lower the threshold for SOICR for significant Ca2+ leak.  However, the 
combination of phosphorylation and mutations/alterations in other proteins that affect RyR2’s 
activity could also drastically lower the threshold for SOICR.  Although the most studied mechanism 
for SOICR to date is the phosphorylation of RyR2, investigating other mechansisms involving 
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proteins that modulate RyR2’s threshold for SOICR is equally important in understanding triggered 
arrythmia.  
1.4 The Influence of Protein-Protein interactions on RyR2 
1.4.1 Junctophilin-2 
Many protein interactions within the RyR2 macromolecular complex that are seen to modulate 
SOICR have been observed to have a ratio mechanism. A great example of this is junctophilin-2 
(JPH2). JPH2 is thought to function as a scaffold protein which stabilises the dyad by linking the 
membranes of the t-tubule and SR to keep them in close association for more effective CICR. This is 
not JPH2’s only function as it is also seen to influence the activity of RyR2 by stabilising the 
macromolecular complex of RyR2 through structural association (van Oort, Garbino et al. 2011, 
Munro, Jayasinghe et al. 2016). It was originally shown to influence RyR2 function in a study by van 
Oort, Garbino et al. (2011). They showed that the loss of JPH2 led to increased SCR from RyR2 
(increased RyR2:JPH2). However, they argued that this was unlikely to be due to SOICR, as a reduced 
SR calcium content was also observed in JPH2 knockdown mice. A study by Beavers, Wang et al. 
(2013) on an E169K mutation in JPH2 built on the findings in van Oort, Garbino et al. (2011) . This 
mutation was found present in patients with a paroxysmal AF phenotype. Transgenic mice expressing 
E169K JPH2 were seen to have increased AF events, due to increased SOICR. This was partially 
thought to be due to reduced association of mutant JPH2 to RyR2, with the domain containing the 
E169K residue being essential to reducing the activity of RyR2 and SOICR.  Interestingly, analysis of 
the right atrial appendage (RAA) of paroxysmal AF patients with E169K mutations showed an 
increase in expression of RyR2. This would cause a decrease in JPH2:RyR2 (or increased RyR2:JPH2), 
functionally reducing the amount of RyR2 channels being modulated by WT JPH2, leading to 
increased SOICR-associated AF. This effect of a ratio on RyR2 is further strengthened by Munro, 
11 
 
Jayasinghe et al. (2016), where JPH2 was overexpressed and RyR2 expression was unaltered, with a 
ratio of 3 JPH2: 1 RyR2. They found that mice overexpressing JPH2 had a reduced Ca2+ spark 
frequency, despite an increased RyR2 cluster size and increased SR content. This supports the idea 
that JPH2 influences RyR2’s propensity for SOICR. Taking all JPH2 studies discussed into 
consideration, it is seen that as we increase JPH2:RyR2, we will see a decrease in Ca2+ sparks frequency 
(SOICR frequency). This effect of changing JPH2:RyR2 shows the importance of viewing the 
mechanisms between RyR2 and associated proteins as a ratio. 
1.4.2 FK506-binding protein 12.6 
This mechanism of imbalance in RyR2 modulation is not limited to JPH2 however. Another 
notable protein that influences RyR2’s propensity for SOICR is FK506-binding protein 12.6 
(FKBP12.6) (Vest, Wehrens et al. 2005). In resting conditions, FKBP12.6 will be bound to RyR2 at 
around 4 FKBPs per RyR2 (Timerman, Jayaraman et al. 1994). A proposed function of FKBP12.6 is 
to stabilize RyR2, thereby decreasing the frequency of Ca2+ sparks and SOICR events (Marx, Reiken 
et al. 2000). It is proposed that when RyR2 is phosphorylated – particularly at S2808 by PKA – 
FKBP12.6 dissociates from RyR2. This was observed by Marx, Reiken et al. (2000), and a decrease in 
contractility and increase in SR calcium leak was noted. These findings have been controversial 
however, being disputed by other groups (Gonano and Jones 2017).  Knockout of FKBP12.6 in mice 
was found to intensify the SR calcium leak associated with exercise-induced sudden death, 
strengthening the theory that FKBP12.6 stabilises RyR2 (Wehrens, Lehnart et al. 2003). A theory of 
FKBP12.6:RyR2 modulation balance similar to the JPH2:RyR2 modulation could also be proposed, 
as FKBP12.6 overexpression studies have reported a decrease in arrhythmia (Vinet, Pezet et al. 2012). 
Unfortunately, the therapeutic potential of FKBP12.6 is not entirely supported by overexpression 
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studies, with other cardiac abnormalities still being present despite overexpression of FKBP12.6 (Bito, 
Biesmans et al. 2013). 
1.5 Calsequestrin 
The skeletal muscle isoform of calsequestrin (CSQ1) was first isolated from the lumen of the 
SR by MacLennan and Wong in the early 70’s, who gave it the name calsequestrin for its ability to 
sequester calcium (MacLennan and Wong 1971). Some years later, a cardiac isoform (CSQ2) was 
isolated (Campbell, MacLennan et al. 1983). Calsequestrin proteins most well-known function is to 
bind Ca2+ at a high capacity but low affinity to buffer Ca2+ within the SR (Faggioni and Knollmann 
2012). Each CSQ2 protein can bind ~60 Ca2+, at many different sites. When binding Ca2+, at lower 
concentrations (0.5 -1 nM) they form front to front dimers with other CSQ proteins. As the 
concentration of Ca2+ increases (~3 mM), they form back to back associations with other dimers to 
create polymers of CSQ (Fig. 1.3) (Park, Park et al. 2004, Wang and Michalak 2020). The 
polymerisation that CSQ undergoes tends to be seen more in CSQ1, with the more relevant CSQ2 
existing as monomers and dimers in physiological conditions (Fig. 1.3) (Wang and Michalak 2020). 
CSQ2 function is not limited to SR Ca2+ buffering however, with evidence for it to influence RyR2’s 




Figure 1-3 Illustration of the proposed mechanism for how both CSQ1 (Casq1) and CSQ2 (Casq2) 
complexes change in structure at differing Ca2+ concentrations. Wang and Michalak (2020). 
 
1.5.1  Calsequestrin interacts with RyR2 directly and indirectly 
The interaction by which CSQ2 influences RyR2 has historically been via two proteins of the 
RyR2 macromolecular complex, triadin 1 (TRD) and junctin (JNC). Early studies in purified bilayers 
showed that expressing RyR2 with TRD and JNC increased the PO of RyR2, but this was rescued by 
introducing expression of CSQ2. However, at higher concentrations of Ca2+ the effect of CSQ2 was 
reduced. These findings lead to the proposed mechanism that JNC and TRD increased the activity of 
RyR2, and that CSQ2 binds to JNC and TRC to destabilise this effect (Gyorke, Hester et al. 2004). 
This mechanism was also thought to explain SOICR, as CSQ2 dissociates from the RyR2 
macromolecular complex in higher Ca2+ concentrations, possibly suggesting that CSQ2 acts as a 
luminal Ca2+ sensor for RyR2 (Gyorke, Hester et al. 2004). This proposed mechanism has been 
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challenged in recent years however. More recent studies have shown that JNC and TRD are not 
needed for CSQ2 to have an effect on SOICR, and that CSQ2 can be directly associated with RyR2 
(Handhle, Ormonde et al. 2016). The current theory for the interaction between RyR2 and CSQ2 is 
that they interact both directly, and indirectly via JNC and TRD (Handhle, Ormonde et al. 2016, Wang 
and Michalak 2020). 
1.5.1.1 CPVT Type II 
Although CPVT is more commonly associated with RyR2 mutations (discussed above), CPVT 
may also be associated with altered CSQ2. Clinical data has shown that mutations within CSQ2 can 
lead to the development of arrhythmia. The second most common form of CPVT – Type 2 CPVT 
(CPVT2) – is related to dysfunction of CSQ2 (Terentyev, Nori et al. 2006), and is thought to account 
for ~4% of CPVT cases (Ackerman, Priori et al. 2011). CPVT2 typically has a more severe phenotype 
than RyR2-associated CPVT, whereby families with high prevalence have an earlier onset of the 
disease, and younger age of death (Lahat, Pras et al. 2001).  
1.5.1.2 Animal Studies 
The link between CSQ2 expression and SOICR associated arrhythmia is well reported in 
animal studies (Chopra, Kannankeril et al. 2007, Yeh, Wakili et al. 2008). A heterozygous knockout of 
CASQ2 (CSQ2 gene) in mice (CSQ2-HK) resulted in a ventricular tachycardia (VT) phenotype 
(Chopra, Kannankeril et al. 2007). Interestingly, the reduction of CSQ2 in CSQ2-HK mice was only 
25% (compared to WT mice), yet this was enough to cause triggered VT. CSQ2-HK-mice had nearly 
triple the amount of SCR events per minute relative to WT mice, with these SCR events attributed to 
SOICR. Another crucial finding of this study was that this CSQ2 loss-associated SOICR was due to 
attenuation of modulation by CSQ2 on RyR2 and not by a loss of CSQ2 buffering. This finding was 
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proved by comparing the free Ca2+ concentration between WT and HK-mice instead of total SR Ca2+, 
negating the effect of Ca2+ bound to CSQ2 (Chopra, Kannankeril et al. 2007). There was no difference 
in RyR2 expression in the Chopra, Kannankeril et al. (2007) study, meaning that the differences 
between CSQ2-HK and WT mice were only in CSQ2 expression, and therefore RyR2:CSQ2. 
Therefore, this study also demonstrates that an increased RyR2:CSQ2 may lead to an arrhythmia 
phenotype.  
1.5.1.3 Cell Culture 
Evidence in cell culture shows that CSQ2 is associated to RyR2 directly. The Handhle, 
Ormonde et al. (2016) study was performed in HEK293 cells expressing both RyR2 and CSQ2, a non-
cardiac cell line that lacks other cardiac proteins, notably TRD and JNC. A pulldown assay showed a 
strong association between RyR2 and CSQ2, demonstrating that JNC and TRD are not essential for 
the association of RyR2 and CSQ2 (indirect association). This direct association of CSQ2 and RyR2 
was also seen to still influence RyR2 susceptibility for SOICR, with less SOICR events seen in cells 
expressing both proteins when compared to cells expressing only RyR2.  
1.5.2 The ratio of CSQ2 and RyR2 
If modest reductions of CSQ2 expression were seen to lead to increased SOICR events in 
mice (Chopra, Kannankeril et al. 2007), then an increase in expression of RyR2 relative to CSQ2 
(decreased CSQ2:RyR2) could have similar effects on RyR2-associated SOICR due to a relative loss 
of RyR2 modulation.  
1.5.2.1 Increased relative RyR2 
Further evidence that RyR2 and CSQ2 are acting in a ratio mechanism in regards to RyR2 
modulation are provided by Voigt, Heijman et al. (2014). This study on the tissue samples of 
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paroxysmal AF patients and found an increased expression of RyR2. This increase of protein 
expression was limited to RyR2, leading to an increased amount of RyR2 relative to CSQ2 (decreased 
CSQ2:RyR2) and other modulatory proteins (JPH2, etc.) (Voigt, Heijman et al. 2014). This relative 
loss of modulatory proteins could lead to the destabilisation of RyR2 and may explain the increased 
amount of SCR events seen in the AF patients of this cohort. It is unclear however, whether the 
increased SCR events are entirely caused by dysfunction of the ratio of RyR2 and modulatory proteins. 
1.5.3 A proposed Model for the effect of RyR2:CSQ2 
If the CSQ2 studies (discussed previously) where a relative loss of CSQ2 is considered 
alongside the Voigt, Heijman et al. (2014) study where increased RyR2, then we can build a model that 
shows how all of these studies findings are acting by a similar mechanism (Fig. 1.4).  In this model, 
either a relative loss of CSQ2 or a relative gain of RyR2 would have the same functional consequences 





Figure 1-4 A Proposed Model for the imbalance of RyR2 and CSQ2 leading to an arrhythmia 
susceptible phenotype. Whether there is a relative gain of RyR2, or a relative loss of CSQ2, both can result 
in an arrhythmia phenotype. Sibbles, 2020. Created with BioRender.com. 
 
1.6 Project Rationale 
Despite changes to RyR2:CSQ2 being implicated in AF, a study is yet to be done to investigate 
the functional effect of changing RyR2:CSQ2, especially in the context of direct association as seen in 
Handhle, Ormonde et al. (2016). Therefore, my project aims to investigate whether a functional direct 
ratio mechanism may exist between RyR2 and CSQ2 and propensity for SOICR. This will be done by 
expressing both RyR2 and CSQ2 in HEK293 cells and then subjecting them to increasing levels of 
Ca2+. By changing the relative expression of these proteins, it is hoped that a functional effect on 
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SOICR may be seen which relies on RyR2:CSQ2. The implications of such a finding could better 
guide future research into therapeutic interventions involving RyR2 and CSQ2. 
1.6.1 Aims 
By using a HEK293 cell model, I am aiming to show: 
1. Co-expression of CSQ2 and RyR2 will reduce the amount SOICR events in HEK293 
cells, when compared to RyR2 only control cells. 
2. CSQ2 can directly influence RyR2 by using a cell model that does not express other 
proteins of the RyR2 macromolecular complex. 
3. Show that by changing RyR2:CSQ2, we will see less SOICR events as we decrease 
RyR2:CSQ2. 
1.6.2 Hypothesis 
Based upon the effects of relative increased RyR2 (Voigt, Heijman et al. 2014) and decreased 
CSQ2 (Chopra, Kannankeril et al. 2007, Yeh, Wakili et al. 2008), I expect as the RyR2:CSQ2 is 
decreased, we will see less SCR overall. I also hypothesise that cells that have a lower RyR2:CSQ2 will 





2.1 HEK293 Cells 
All HEK293 cells used in this study were donated from the Jones lab. They were previously 
generated as described in Jiang, Wang et al. (2005) by Professor Wayne Chen (University of Calgary). 
These HEK293 cells stably express a protein of interest via a tetracycline induced vector (described 
below). The two proteins of interest (POI) that are stably expressed by this inducible vector system 
are either wild type RyR2 (RyR2wt), or a fusion protein of RyR2 and green fluorescent protein (RyR2-
GFP). 
2.1.1 Storage and Thawing of Cells 
1 mL aliquots of both cell lines used in this project are stored in a dimethyl sulfoxide (DMSO) 
freezing medium at -80°C until needed. Thawing of these cells is initially done by briefly warming the 
tube of frozen cells in the 37°C water bath. The slightly thawed cell mix is then transferred to T75 
flasks with 30 mL of pre-warmed supplemented Dulbecco's Modified Eagle Medium (DMEM+: 1.8 
mM CaCl2, 25 mM D-Glucose, 5.3 mM KCl, 4 mM L-Glutamine, 0.8 mM MgSO4, 110 mM NaCl, 
44 mM NaHCO2, 0.9 mM NaH2PO-H2O, pH 7.4) supplemented with 10% fetal bovine serum 
(FBS), 1% non-essential amino acids, 1% streptomycin, and 1% penicillin. The DMEM+ will thaw 
the cells further and dilute the DMSO (thereby helping to negate DMSO’s negative effect on 
cell growth). The media is replaced after 24 hours to further dilute remaining DMSO. HEK293 cells 
are grown in a humified incubator at 37°C with an atmosphere of 5% carbon dioxide (CO2). When 
cells reach full confluence, they are passaged into a T25 flask. 
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2.1.2 Passaging Cells 
Cells were grown in T25 flasks in DMEM+ until around they reached 90% confluence, then 
they are ready to be passaged. Cells are passaged by removing old media and washed twice with 2 mL 
of phosphate buffered saline (PBS; 2.7 mM KCL, 1.8 mM KH2PO4, 137 mM NaCl, 10 mM 
Na2HPO4, pH 7.4), and then are left in 1 mL of PBS. The flask is then transferred to the incubator 
for five minutes to allow the cells to detach from the bottom of the flask. After this brief incubation, 
the cells are agitated to further encourage cells to detach from the flask. 7 mL of DMEM+ are then 
added and cells are pipetted gently once again to make a homogenous cell mix. This cell mix is then 
added to a new flask with DMEM+ to create a new passage. The ratios of cell mix to DMEM+ that 
is added to the new flask are summarised in Table 2.1, and are based on the time it will take cells to 
reach 90% confluence. Cells are grown in the incubator until they reach 90% confluence, and are then 
passaged and/or used to make a plate. An inverted microscope (Olympus CKX41) is used to assess 
cell confluence. The absence of biological contaminants is confirmed by microscope and by a lack of 
opacity in the media. Cells are only used from passages 2-9. 
Table 2-1 Summary of the ratios used when creating a new passage. Cells should be at ~90% 
confluence on the day of next use. 
Day of next use Ratio Cell mix : Media 
1 Day 1:1 3.75 mL : 3.75 mL 
2 Days 1:2 2.5 mL : 5 mL 
3 Days 1:4 1.5 mL : 6 mL 
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2.1.3 Preparation of HEK293 Cells for Imaging 
For cells to be imaged in our single cell Ca2+ imaging protocol, they must be grown on 13 mm 
diameter circular coverslips. This is done by first sterilising coverslips in 70% ethanol and then placing 
coverslips into a well of a 6-well plate. Each well of the plate fits 3 coverslips. Poly-L-lysine was then 
applied to the coverslips for five minutes to provide a structure for cells to attach onto the coverslips 
more easily. 1 mL of a 1:6 (1 mL cell mix to 6 mL DMEM+) is then added to 2 mL of DMEM+ in 
each well of the plate. After 24 hours of making a plate, cells are transfected (or mock transfected) 
with the appropriate plasmid of complementary DNA (cDNA). 
2.1.3.1 Transfection 
To introduce CSQ2 cDNA into our HEK293 cell model, a widely used Ca2+-phosphate 
precipitation method was used. This method allowed cDNA to be endocytosed by cells (Graham and 
Van Der Eb 1973). A mixture of CaCl2 (248 mM) and cDNA made up to 1 mL with milliQ water is 
added in a dropwise manner to HEPES buffered saline (2xHEPES: 50 mM HEPES, 274 mM NaCl, 
1.8 mM Na2HPO4∙7H2O, pH 7.05) whilst swirling by hand. 180 μL of this Ca
2+-phosphate mix is then 
added dropwise in a spiral pattern to each desired well 24 hours after the preparation of the plate.  
For the CSQ2wt single cell Ca2+ imaging experiments with Fluo-4-AM, there were four 
different conditions. Each of these conditions required a different concentration of cDNA to be 
transfected (donated from Jones lab, previously generated by Professor Wayne Chen): 1) No CSQ2 
(mock transfection). 2) 0.5 μg/mL CSQ2wt cDNA, 3) 1.0 μg/mL CSQ2wt cDNA, and 4) 2.0 μg/mL 
CSQ2wt cDNA. For the tagged cDNA used in the tagged-CSQ2 experiments, we only used CSQ2-
N-P2A-mCherry (CSQ2-N-P2A-mCh).  This was transfected with a concentration of 1 μg/μL cDNA. 
22 
 
2.1.3.2 Generation of Fluorescently Tagged CSQ2 
Generation of a fluorescently tagged CSQ2 cDNA was done by GenScript. The fluorescent 
tag was mCherry (mCh). The tag was linked to the N-terminus of CSQ2, either directly (CSQ2-N-
Tag) or with a P2A “self-cleaving” peptide (CSQ2-N-P2A-Tag)(Liu, Chen et al. 2017) between the 
fluorescent tag and CSQ2. This CSQ2-N-P2A-Tag would cause the protein to be cleaved into a 
fluorescent protein (mCh) and an effectively wild type CSQ2. To reduce the likelihood of these 
fluorescent tags affecting our results, we only used CSQ2-N-P2A-mCh for our Ca2+ imaging 
experiments.  
2.1.3.3 Induction of RyR2wt/RyR2-GFP 
The HEK293 cells used in this study are able to stably express either RyR2wt or RyR2-GFP 
via a tetracycline induction method (Jiang, Xiao et al. 2004). The addition of 
tetracycline (Sigma-Aldrich) would inactivate the TET-mediated suppression of RyR2wt/RyR2-GFP 
gene and allow expression of the protein. To induce cells, each well is first washed with 2 mL of 
DMEM+ twice. After washing, 3 mL of DMEM+ with 0.1 μg/mL tetracycline is added to each well. 
Inducing of cells is done ~24 hours after transfection, but also 16 hours before the intended start of 
































































Figure 2-1 Timeline for the preparation of HEK293 Cells. 
 
2.2 Single Cell Ca2+ Imaging 
To assess the effect of different RyR2:CSQ2 on SOICR, an established SOICR protocol that 
is extensively used within the Jones lab was used (Jiang, Xiao et al. 2004, Jones, Meng et al. 2008, 
Zhang, McLay et al. 2014, Zhang, Waddell et al. 2016). Coverslips (prepared as described above) were 
loaded with a Ca2+ dye by taking a coverslip from the plate, washing briefly in Ca2+-free Krebs-Ringer 
HEPES buffer (KRH: 6 mM D-glucose, 5 mM KCl, 1.2 mM MgCl2, 25 mM HEPES, 125 mM NaCl, 
pH 7.4) and then incubated in 1 mL of a Bovine serum albumin (BSA)/KRH solution (1 mg/mL BSA 
in KRH) containing 2 μM of dye (either Fura-2-AM or Fluo-4-AM dissolved in DMSO with 12% 
pluronic acid; Life Technologies, NZ) for 10 minutes. Coverslips loaded with dye were then washed 
in KRH for another 10 minutes, which allows for de-esterification of the dye to occur. Coverslips 
were then mounted onto a perfusion chamber by using laboratory grease. Mounted coverslips are 
superfused by a simple perfusion system with Ca2+-free KRH until a suitable area of the coverslip was 
located via the use of the eyepiece of the microscope (Nikon Eclipse Ti). After finding an area for 
24 
 
imaging and all relevant images (Fura-2, mCh, and GFP) were obtained, recording will begin. After 2 
minutes of baseline recording in Ca2+-free KRH, the cells were sequentially superfused with KRH 
containing increasing concentrations of CaCl2 for 4 minute intervals from 0.1 – 1.0 mM (Table 2.2). 
For the final perfusion, KRH + 1.0 mM CaCl2 + 20 mM caffeine (Sigma Aldrich) was used to cause 
a caffeine induced Ca2+ release from all viable cells expressing RyR2. This is because caffeine is a RyR2 
agonist (Kong, Peter et al. 2008) and can therefore cause a single transient fluorescence spike.  After 
imaging, coverslips were left in a 4% bleach solution until disposed of. All recordings were done via 
the use of the imaging software (NIS Elements AR 4). 
 
Table 2-2 Summary of duration of perfusion at each [Ca2+] for CSQ2wt and CSQ2-P2A-mCh 
experiments. 
 Time for each condition (minutes) 






0 (Baseline) 2 2 
0.1 4 4 
0.2 4 4 
0.3 4 4 
0.5 4 4 
1.0 4 10 




2.2.1 Fluo-4-AM and CSQ2wt imaging 
The dye used for the CSQ2wt imaging sessions was Fluo-4-AM (Invitrogen). This is an 
acetoxymethyl ester (AM) form of the Ca2+ indicator, which is membrane permeable. Fluo-4-AM was 
dissolved in DMSO and 12% pluronic acid and stored at -20°C. When required, this Fluo-4-AM mix 
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was thawed in warm water and 1 μL was added to a BSA/KRH mix, to a final concentration of 2 µM 
(as described above). When Ca2+ binds to Fluo-4-AM while being excited by a 488 nm LED, a 
florescence proportional to the amount of cytosolic Ca2+ is emitted (Gee, Brown et al. 2000). This was 
used to measure the amount of spontaneous Ca2+ released. The emission peak of Fluo-4-AM with 
Ca2+ bound is 488 nm, which means that it cannot be used with proteins like GFP that would have 
significant overlap of emission. For this reason, a change of dye from Fluo-4-AM was required when 
imaging with RyR2-GFP (as it also has an excitation of 488 nm). Hence, Fura-2-AM (Invitrogen) was 
used in later experiments. 
2.2.2 Fura-2-AM and CSQ2-mCh Imaging 
The Fura-2 used in the tagged protein imaging sessions was also an AM form, meaning that it 
was cell permeable but also required time for de-esterification (the 10 minutes in KRH after loading 
with dye, as described in 2.1.5). The main difference between Fluo-4 and Fura-2 is that Fura-2 is a 
ratiometric dye (Tinning, Franssen et al. 2018). Images are taken at both 340 nm and 380 nm and the 
ratio of these two wavelengths (calculated by the imaging software, NIS Elements AR 4) will show if 
there is Ca2+ present. The primary reason for the use of Fura-2 (340/380nm) was due to the lack of 
overlap with other proteins of interest, GFP (488 nm) and mCh (587 nm) (Fig. 2.2).  
The protocol for imaging was also slightly altered, with the time that cells are superfused with 
1.0 mM CaCl2 being extended from 4 to 10 minutes. This was to allow for measurement of SOICR 




Figure 2-2. Relative excitation plot of each dye/fluorescent protein. From left to right: Fura-2 
Ca2+ bound, Fura-2 Ca2+ free, GFP, mCherry. The fluorescence peaks of each of the fluorophores do not 
overlap with each other enough to affect measured fluorescence. Made in www.fpbase.org. 
 
2.2.3 Analysis of Single Cell Ca2+ Imaging 
NIS Elements AR 4 was used for the analysis of the single cell Ca2+ imaging recordings. Within 
the software, each cell was circled as an individual region of interest (ROI) and then the fluorescence 
was measured over time to ascertain whether the cell had SOICR, and at what concentration of Ca2+ 
the SOICR occurred at. Only cells that had an observable caffeine-induced Ca2+ release were included 
in the analysis, to ensure that only viable cells were analysed. We also excluded cells that had a SOICR 
during the 0 mM Ca2+ at the start of the recording, as it was likely they were not viable enough for our 
protocol. For the oscillation experiments, each cell was measured and then the Ca2+ concentration at 
which the first SOICR occurred at was tallied. If a cell had a SOICR at a certain concentration of Ca2+, 
it was then said to be oscillating regardless of whether or not it had more SOICR events at higher 




To confirm the presence of proteins of interest (POI) and also confirm the co-localisation of 
these proteins, immunohistochemistry was used. HEK293 cells were prepared as described above, 
except with a shorter duration of time (8-10 hours) spent with the transfection precipitate to reduce 
the likelihood of cells losing adhesion to the coverslip. We tested three of our four generated 
fluorescently tagged CSQ2 cDNA (only CSQ2-N-P2A-GFP was not used due to not being available 
at the time of testing, and also not being used for further experiments). After cells were prepared, a 
coverslip from each well was then imaged on the inverted microscope (Nikon Eclipse Ti) to confirm 
CSQ2-N-Tag/CSQ2-N-P2A-Tag was present. Once a successful transfection was confirmed for each 
condition, each well was washed twice with 1-2 mL of PBS, and then fixed with 2% paraformaldehyde 
(PFA) in PBS at room temperature. After 5 minutes of exposure to PFA, the cells were washed once 
again with PBS and then stored in fresh PBS at 4°C until needed. 
When required, each coverslip was washed three times with PBS for 10 minutes each. They 
were then blocked with 40 μL of 10% normal goat serum (NGS) for one hour. They were then rinsed 
with PBS and then blotted. 40 μL of an incubation solution (PBS, 1% BSA + 0.05% NaN3, 0.05% 
Triton) containing the primary antibodies (Table 2.3) at the appropriate dilution was then added to 
the coverslips. Coverslips were left in the antibody incubation solution overnight at 4°C.  
Table 2-3 Primary antibodies used to detect the POI. 













After incubation with the primary antibodies, the coverslips were washed three times with PBS 
for 10 minutes each.  Coverslips were then blotted, and 40 μL of an incubation solution containing 
the secondary antibodies was added (Table 2.4). As the coverslips often had GFP or mCh present, 
secondary antibodies were carefully selected to eliminate overlap excitatory wavelength. Wheat germ 
agglutinin 405nm (WGA) was also added to the incubation solution to visualise the plasma membranes 
of the cells, with a final dilution of 1:200. 
 
Table 2-4 Secondary antibodies used to detect POIs.  



















































































After 2 hours of incubation with the secondary antibodies at room temperature, the coverslips 
were washed 3 times with PBS for 10 minutes.  Coverslips were then blotted and mounted onto slides 
using Prolong Gold mountant (Life Technologies, NZ). Images of the cells were obtained by the use 
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of a confocal microscope (Nikon A1R Multi-Photon Confocal Laser Scanning Microscope) from 
Otago Micro and Nanoscale Imaging (OMNI).  
2.4 Image analysis  
For our Fluo-4 imaging analysis, each individual ROI (an ROI being an individual cell) was 
tallied for the Ca2+ concentration at which they first exhibited a SOICR event (from 0.1 mM [CaCl2] 
– 1.0 mM [CaCl2] + 20 mM [Caffeine]). This tally was then converted into the percentage of cells 
exhibiting Ca2+ leak at each [CaCl2]o for each coverslip (Microsoft Excel). This data was then 
transferred to our graphing/statistical analysis software (GraphPad Prism v8) and a mean for [CaCl2]o 
for each condition was calculated.  
For the Fura-2 analysis, we first used our images of the mCh fluorescence to obtain a ROI for 
each mCh positive cell (cells that were able to be clearly distinguished from the background). This 
ROI was then used to obtain mean intensity for both the GFP fluorescence and the mCh fluorescence. 
The same ROI was also used for our Ca2+ recordings. For this Ca2+ recording, each ROI was tallied 
for the Ca2+ concentration they exhibited their first SOICR event (as described above for Fluo-4 
analysis), as well as the number of SOICR events that occurred during the entire 1.0 mM [CaCl2] 
exposure period. As we had both mCh and GFP fluorescence measurements, these were expressed  
as a ratio: 
Equation 2-1 Calculation of the mCh:GFP ratio. 
𝑚𝐶ℎ 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑚𝑒𝑎𝑛 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 (𝐴𝑈)
𝐺𝐹𝑃 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑚𝑒𝑎𝑛 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦(𝐴𝑈)




Using this ratio, cells from each coverslip were organised into 3 groups: Low mCh:GFP 
(mCh:GFP < 1.3599), Medium mCh:GFP (mCh:GFP = 1.36 – 3.011), High mCh:GFP (mCh:GFP > 
3.012). The ranges for these groups were chosen to make three equal groups for our final analysis. 
The number of SOICR events that occurred during the exposure to 1 mM [CaCl2] was 
normalised to calculate the SOICR frequency (Events/min; FoE). The equation for this normalisation 
being: 
Equation 2-2. Calculation of normalised FoE. 
# 𝑜𝑓 𝑆𝑂𝐼𝐶𝑅 𝑒𝑣𝑒𝑛𝑡𝑠 𝑡ℎ𝑎𝑡 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑑
𝑇𝑜𝑡𝑎𝑙 𝐸𝑥𝑝𝑜𝑠𝑢𝑟𝑒 𝑇𝑖𝑚𝑒 (𝑖𝑛 𝑠𝑒𝑐𝑜𝑛𝑑𝑠)
 𝑥 60 = 𝑆𝑂𝐼𝐶𝑅 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 (𝑒𝑣𝑒𝑛𝑡𝑠/𝑚𝑖𝑛) 
2.5 Statistical Analysis Section 
Unless otherwise stated, data is expressed as a mean ± standard error of the mean (SEM). For 
experiments investigating the percentage of cells exhibiting Ca2+ leak, we used a repeated measures 
two-way analysis of variance (RM 2-way ANOVA) to assess statistical significance.  For the grouped 
analysis of FoE, a one-way analysis of variance (1-way ANOVA) was used to assess statistical 
significance. For the individual cell FoE, a linear regression line of best fit was calculated for the data. 
From this line an R2 was calculated, and a non-zero null hypothesis test was carried out. A p-value of 




The aim of this research project was to investigate the effect of changing the ratio of RyR2 
and CSQ2 expression on SOICR within a HEK293 cell model. It was hypothesised that as we 
increased the relative expression of CSQ2 to RyR2 within cells, we would see less SOICR in those 
with a lower RyR2:CSQ2 (or a higher CSQ2:RyR2).  
3.1 Fluo-4 HEK293 Imaging with RyR2-wt and CSQ2-wt 
   
Figure 3-1. Left: HEK293-RyRwt cells (from the Control group) undergoing caffeine-induced Ca2+ 
release. These cells were from a relatively late passage (8) and so have more prominent processes.  Right: 
The same cells with examples selected as regions of interest (ROIs). Only cells that were responsive to 
caffeine and were not densely surrounded by other cells were selected for analysis. 
 
3.1.1 Increasing the amount CSQ2 cDNA transfected into HEK293 cells reduced SOICR 
In our first experiment, we used HEK293 cells with an inducible, stably-expressed RyR2-wt 
vector. These were transfected with varying concentrations of CSQ2-wt cDNA. When subjected to 
our Ca2+ imaging protocol and subsequent image analysis, we observed a general trend that by 
increasing the amount of CSQ2 cDNA transfected, we saw a lower percentage of cells exhibiting Ca2+ 
leak (SOICR events) at each concentration of CaCl2 (Fig. 3.2). This was most evident at the 0.5 mM 
CaCl2 point, where coverslips that were transfected with the highest CSQ2 cDNA concentration (2 
µg/mL) appeared to demonstrate a lower percentage of cells exhibiting Ca2+ leak (2 µg/mL mean 
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=27.5%) compared to 0.5 µg/mL CSQ2 cDNA transfected (0.5 µg/mL mean=34.6%) and control 
coverslips (control mean =40.9%). However, for the 0.2 and 0.3 mM CaCl2 exposure, there was no 
observable difference between the CSQ2 cDNA transfected and control groups. Although there was 
an apparent trend for reduced SOICR activity with increasing CSQ2 cDNA transfection, no 
statistically significant differences between groups were found (RM 2-way ANOVA).  However, the 
overall trend observed in reducing SOICR activity with increasing CSQ2 cDNA transfection indicated 
that further investigation was warranted by using an alternative approach, using such as fluorescently 
tagged proteins to overcome potential limitations of this initial methodology (see section 4.1.1). 
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Figure 3-2 The Effect of Increasing [CSQ2wt cDNA] transfected into HEK293 cells on the 
percentage of cells exhibiting Ca2+ leak.  HEK293-RyR2wt cells transfected with different concentrations 
of CSQ2wt cDNA and loaded with Ca2+ indicator (Fluo-4-AM). Control (mock transfection, n = 7; black line), 
0.5 μg/mL CSQ2wt (n=9; blue line), 1.0 μg/mL CSQ2wt cDNA (n=6; red line), 2.0 μg/mL CSQ2wt cDNA (n=7; 
green line). Each n value represents a separate experiment. Data shown as % mean ± SEM. These data 
were not statistically significant between groups (RM 2-way ANOVA). 
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3.2 Immunocytochemistry Results 
To validate our generated fluorescently tagged CSQ2 cDNA, we investigated mCh-positive 
cells to confirm they were also positive for CSQ2 expression, and that CSQ2 was co-localised with 
RyR2 in the ER. This was done using immunocytochemistry for RyR2 and CSQ2 (Table 2.3) with 
fluorescent secondary antibodies which were spectrally-separated from the mCh present in the sample 
(Table 2.4).  
3.2.1 Successfully Transfected Cells were Present Prior to Fixing 
Before subjecting coverslips to our immunocytochemistry protocol, successful transfection 
was first confirmed using an epifluorescent microscope. For all fluorescently tagged CSQ2 cDNA that 
were tested, we were able to detect mCh positive cells in live cells prior to fixation.  
3.2.1.1 CSQ2-mCh in Live Cells 
Imaging of the CSQ2-N-mCh transfected cells (Fig. 3.3 Left), revealed a distinct perinuclear 
pattern of mCh fluorescence.  This was most likely associated with the mCh being distributed to the 
endoplasmic reticulum (ER) of the cells (with the ER in non-cardiac cells being analogous to the SR 
in cardiac cells), which is the expected localisation of CSQ2 (Wang and Michalak 2020). The HEK293 
cells transfected with CSQ2-N-P2A-mCh cDNA (Fig. 3.3 Right) demonstrated a differential pattern 
of fluorescence compared to the CSQ2-N-mCh. Unlike in the directly linked CSQ2-N-mCh cDNA, 
a distinct perinuclear distribution was no longer visible in these mCh positive cells.  Instead a relatively 
consistent intensity of mCh fluorescence was evident throughout the whole cell. This indicates that 





   
Figure 3-3.  Images of live HEK293 cells transfected with mCherry-tagged CSQ2 cDNA. 
Epifluorescent images of: Left: CSQ2-N-mCh transfected HEK293-RyR2wt cells. Right: CSQ2-N-P2A-mCh 
transfected HEK293-RyR2wt cells. Images were acquired of live cells using a 10X lens. 
 
3.2.2 Labelled HEK293-RyRwt cells 
After fixing and subjecting cells to our immunocytochemistry protocol (as described in Section 
2.3), we observed that the overall density of cells present on the coverslips had greatly decreased on 
all slides, most likely being due to the fixation process with PFA. Despite this loss however, we were 
still able to identify mCh positive cells in our CSQ2-N-mCh coverslips (Fig. 3.4). In these cells, there 
was also an overlap in the localisation of mCh and CSQ2 fluorescence. This overlap indicates that the 
CSQ2-N-mCh fluorescent tag was linked to the CSQ2 protein when expressed in cells. We also saw 
that there was overlap with the RyR2 labelling in the cells, indicating co-localisation within the ER.  
 Unfortunately, insufficient numbers of the CSQ2-N-P2A-mCh transfected cells were retained 
on the coverslips following the fixation and immunocytochemistry process to enable characterisation 
of protein expression and co-localisation within these cells (Fig. 3.5).  However, based on the presence 
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of live mCh-positive HEK293 cells prior to fixation, and the identification of CSQ2 labelling in the 
CSQ2-N-mCh positive cells, we proceeded to use the CSQ2-N-P2A-mCh cDNA to investigate the 
effect of CSQ2 expression on RyR2 Ca2+ leak.  No CSQ2 labelling was identified in HEK293 cells 
which were negative for mCh fluorescence or in mock transfection cells (Fig. 3.4-3.6), confirming that 
these cells do not endogenously express CSQ2 (Handhle, Ormonde et al. 2016). 
3.3  Fluorescently tagged imaging 
For the fluorescently tagged single cell Ca2+ imaging sessions, the cell line was changed to one 
expressing an inducible HEK293-RyR2-GFP and was transfected with CSQ2-N-P2A-mCh cDNA. 
This change in protocol allowed us to observe which cells on a coverslip were expressing both RyR2 
(GFP) and CSQ2 (mCh). For the following results, after loading cells with Fura-2 and before starting 
the single cell Ca2+ imaging protocol, images were collected of cells excited at 380 nm (to show all 
cells), 488 nm (to show RyR2-GFP expression), and at 587 nm (to show CSQ2-N-P2A-mCh 
expression) (Fig 3.7). By using these images, an expression ratio of CSQ2:RyR2 (mCh:GFP) could be 














Figure 3-4 mCh-positive HEK293 cells express CSQ2.  Confocal images of (A) plasma 
membrane (WGA, blue), (B) RyR2 (green), (C) mCh (red) and (D) CSQ2 (grey) labelling in fixed 
HEK293-RyR2 cells transfected with CSQ2-N-mCh cDNA.  (E) Merged image of all channels 













Figure 3-5 mCh-positive HEK293 cells are lost after fixation. Confocal images of (A) 
plasma membrane (WGA, blue), (B) RyR2 (green), (C) mCh (red) and (D) CSQ2 (grey) labelling in 
fixed HEK293-RyR2 cells transfected with CSQ2-N-P2A-mCh cDNA.  (E) Merged image of all 













Figure 3-6 Control HEK293 cells do not express CSQ2. Confocal images of (A) plasma 
membrane (WGA, blue), (B) RyR2 (red), (C) GFP (green) and (D) CSQ2 (grey), (E) Merged image 













Figure 3-7 A coverslip of HEK293-RyR2-GFP transfected with CSQ2-N-P2A-mCh 
cDNA. A) All cells (Cells loaded with Fura-2-AM), B) Cells expressing RyR2-GFP (cells excited 
by 488nm LED) C) Cells expressing CSQ2 (same cells excited by 587nm LED) D) Merge of B and 
C (cells that are yellow are co-expressing RyR2 and CSQ2). 
3.3.1 Comparison of controls 
To verify that the activity of GFP-tagged RyR2 was comparable to that of the wild-type RyR2 
used previously, we first assessed the SOICR activity of these cells.  Analysis revealed that these two 
HEK293 cell lines stably expressing either RyR2wt or GFP-tagged RyR2 showed no significant 
differences in Ca2+ leak in response to increasing [Ca2+]O (Fig. 3.8).  The mCh-negative cells within 
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CSQ2-N-P2A-mCh transfected samples were also assessed which demonstrated a similar SOICR 
activity response as the control RyR2-GFP cells.  This indicates that any changes in SOICR response 
observed in mCh-positive cells was a consequence of the cDNA transfection and not due to RyR2 
activity being modified by the GFP-tag.  
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Figure 3-8 Comparison of controls from each experiment. Control RyR2wt (n=7; black square), 
Control RyR2-GFP (n=5; green circle), mCherry negative cells (n=12; blue triangle). Each n value represents 
a separate experiment. Data shown as % mean ± SEM. RM 2-way-ANOVA showed no statistically 
significant difference between groups. 
 
3.3.2 Transfection Efficiency Analysis 
As the mCh fluorescence was visible in the live cells prior to Ca2+ imaging, we were able to 
investigate the transfection efficiency (T%) in our CSQ2-N-P2A-mCh cDNA transfected samples. 
Two randomly selected coverslips from each imaging day had the number of mCh positive cells 
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calculated as a percentage of the total Fura-2 loaded cells (from the images taken before recording 
Ca2+ leak). Results for this analysis are summarised in table 3.1. The T% was found to be highly variable 
not just between days, but also between different wells on the plate. 
Table 3-1 Analysis of T% of 6 of the 12 CSQ2-N-P2A-mCh coverslips that were imaged. The 
“coverslip” column denotes which coverslip it was on its imaging session (E.g. 1st was the first coverslip to 
be imaged on that imaging session). 
Coverslip Date Imaged Total Cells mCh Cells T% 
1st CSQ2-N-P2A-
mCh 
03/09 87 21 24% 
4th CSQ2-N-P2A-
mCh 
03/09 198 28 14% 
1st CSQ2-N-P2A-
mCh 
27/08 535 37 7% 
2nd CSQ2-N-P2A-
mCh 
27/08 573 106 18% 
2nd CSQ2-N-P2A-
mCh 
28/08 207 19 9% 
3rd CSQ2-N-P2A-
mCh 
28/08 229 22 10% 
   
Average 
± SEM 
14% ± 2.5 
 
3.3.3 Effect of altered CSQ2:RyR2 on propensity for SOICR  
As described earlier (Section 2.2.2), the HEK293 cells transfected with mCh-tagged CSQ2 
were subjected to our modified Fura-2 imaging protocol. All mCh positive cells (n=397) were further 
analysed after being divided into three groups based on fluorescence ratio (as described in 2.4): lLow 
mCh:GFP (mCh:GFP < 1.3599, n = 131), mMedium mCh:GFP (mCh:GFP = 1.36 – 3.011, n = 134), 
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hHigh mCh:GFP (mCh:GFP > 3.012, n = 132). The mean fluorescence ratio for each group was: low 
mCh:GFP  = 1.05, medium mCh:GFP = 2.06, high mCh:GFP = 6.11. 
When we analysed the mCh positive cells, we observed that as mCh:GFP was increased 
between groups we also saw a lower percentage of cells exhibiting Ca2+ leak events at each [CaCl2]o 
(Fig. 3.9). Statistical analysis of this data confirmed significant differences between groups, particularly 
between our low mCh:GFP and high mCh:GFP groups (summarised in ST. 1 of the appendix). For 
all [Ca2+]O between 0.2-1.0 mM, the high mCh:GFP group showed a significantly lower proportion of 
cells undergoing SOICR events compared to the low mCh:GFP group.  At 0.3 mM [Ca2+]o, the 
propensity for SOICR in the high mCh:GFP group was also lower than the medium mCh:GFP group 
(36% and 47%, respectively; p= 0.0264).   
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Figure 3-9 The effect of increasing mCh:GFP (CSQ2:RyR2) on the percentage of cells exhibiting 
Ca2+ leak in response to increasing [Ca2+]O in mCh-positive cells. 0.2: Low vs High (p=0.034). 0.3: Low vs 
High (p=0.0096), Medium vs High (p=0.0264). 0.5: Low vs High (p=0.0121). 1.0: Low vs High (p=0.0288). 
Data collected from 12 separate experiments. Data displayed as mean ± SEM. Analysed by repeated 
measures two-way ANOVA with post-hoc multiple comparisons. 
 
3.3.4 Effect of CSQ2 presence on RyR2 associated Ca2+ leak 
To determine the overall effect of CSQ2 presence on SOICR activity, we also compared our 
mCh:GFP fluorescence groups to cells within the same coverslips which were mCh-negative..negative. 
When these cells were analysed and compared to our mCh-positive cells, we found that they had a 
similar percentage of cells exhibiting Ca2+ leak to our medium mCh:GFP cells (Fig. 3.10). When we 
analysed the data for statistical significance (RM 2-way ANOVA), we found some significant 
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differences, particularly between the low and high mCh:GFP, and the high mCh:GFP and mCh 
negative cells (Table. 6.2). 
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Figure 3-10 The Effect of Increasing mCh:GFP (CSQ2:RyR2) on the percentage of cells exhibiting 
Ca2+ leak in cells that were positive for mCh, with mCherry negative cells included. 0.2: High vs mCh Neg 
(p=0.0325). 0.3: Low vs High (p=0.0172), Medium vs High (p=0.0465), High vs mCh Neg (p=<0.0001). 0.5: 
Low vs High (p=0.0218), High vs mCh (p=0.008). 1.0: Low vs High (p=0.0499). Data collected from 12 
separate experiments. Data displayed as mean ± SEM. Analysed by repeated measures two-way ANOVA 
with post-hoc multiple comparisons. 
 
3.3.5 Frequency of Ca2+ Release is Dependant on RyR2:CSQ2 
Due to the extended time we expose our cells to 1.0 mM CaCl2 in our Fura-2 imaging sessions 
(Section 2.2.2), we are able to obtain additional data from these coverslips. By analysing the number 
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of SOICR events that occur within the 10 minutes of exposure to 1.0 mM CaCl2, we are able to 
calculate the normalised frequency of these events (SOICR per min) (Equation 2.2).  
3.3.5.1 Grouped analysis of FoE 
When we analysed the frequency of SOICR events (FoE) in the same groups that were 
generated in the previous fluorescent protein-tagged imaging experiments, we found that the mean 
FoE decreased as the mCh:GFP increased between groups (Fig 3.11). This observation was confirmed 
following statistical analysis (one-way ANOVA with post-hoc multiple comparisons). Interestingly, 
we found that, similar to SOICR propensity results (Fig 3.10), mCh-negative cells had lower FoE 
(lower SOICR activity) than our low mCh:GFP cells (mCh negative mean =0.22; low mCh:GFP mean 
=0.29; p = 0.0326). We also observed a statistically significant difference between the mCh-negative 
cells and high mCh:GFP cells (high mCh:GFP mean =0.16; p =0.379), the low mCh:GFP cells vs 
medium mCh:GFP cells (med mCh:GFP mean = 0.19; p=0.0008), and the low mCh:GFP cells vs 








































































Figure 3-11 mCh:GFP ratio impacts the FoE for Ca2+ leak. Analysis of the normalised frequency of 
SOICR events in 1 mM [Ca2+]O for the varying mCh:GFP fluorescent cells. Data displayed as mean ± SEM. 
For mCh Negative cells (mean = 0.2224; n = 147, from 6 coverslips), and mCh positive cells (Low mCh:GFP 
n=131, Medium mCh:GFP n=134, High mCh:GFP n=132, total n=397, from 12 coverslips). 1-way ANOVA 
with multiple comparisons: mCh Negative vs Low mCh:GFP (p=0.0326), mCh Negative vs High mCh:GFP 
(p=0.0379), Low mCh:GFP vs Medium mCh:GFP (p=0.0008), Low mCh:GFP vs High mCh:GFP (p<0.0001). 
 
3.3.5.2 Individual analysis of FoE 
In addition to the means based on mCh:GFP groups, we also assessed the relationship 
between mCh:GFP fluorescence with FoE combined for all mCh-positive cells (n=397) (Fig. 3.12C). 
We were also able to determine the effect of increasing each fluorescent protein individually on FoE 
47 
 
(Fig. 3.12 A&B). When we analysed at the effect on FoE of increasing CSQ2-N-P2A-mCh in cells 
also expressing RyR2-GFP (Fig. 3.12A), we found a statistically significant non-zero effect of 
increasing mCh fluorescence on reducing FoE (Y = -5.574e-005*X + 0.2593; R2 = 0.0437; p = <0.0001). 
Based on the grouped data analysis, this finding was not unexpected and demonstrates a significant 
negative correlation between increasing CSQ2 expression and reduced SOICR activity. These data are 
in agreement with the overall trend observed with the CSQ2wt experiments (Fig. 3.2). When we 
considered only GFP fluorescence (RyR2-GFP), we saw a statistically significant non-zero relationship 
where as GFP fluorescence increased, there was a significant correlation with increasing FoE (Y = 
0.000486*X + 0.08486; R2 = 0.02583; p =0.0013). This matches previous data collected in the Jones 
lab, whereas cells express more RyR2, more SOICR events are seen (unpublished data).  
When we consider the ratio of mCh:GFP within each individual cell, we find that as we 
increase this ratio, cells have a lower FoE (Fig 3.12A). The line fitted for this data was also significantly 
non-zero (Y = -0.01694*X + 0.2657; p<0.001), and had a higher R2 value (0.05848) than those seen 
individually in figures 3.12A&B. Overall, the results of our individual FoE analysis match what was 
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Figure 3-12. Cells with less GFP fluorescence, or more mCh Fluorescence, or a lower mCh:GFP 
have a lower FoE.  Analysis of the normalised frequency of SOICR events in 1 mM [Ca2+]O for cells positive 
for both GFP and mCh fluorescence. A). Cells arranged by their GFP fluorescence (n =397; Y = 
0.000486*X + 0.08486; R2=0.0258; p =0.0013) B). Cells arranged by their mCh fluorescence (n =397; Y 
= -5.574e-005*X + 0.2593; R2=0.0437; p <0.0001) C). Cells arranged by their mCh:GFP (n =397; Y = -






Throughout the literature it has been demonstrated that an increase in RyR2 relative to 
modulatory proteins - such as CSQ2 – can result in arrhythmogenic phenotypes, with increased Ca2+ 
leak via RyR2 (SOICR). It is also well documented that a relative loss of these regulatory proteins may 
lead to arrhythmia. Some proteins within the RyR2 macromolecular have even been proven to act in 
a ratio relationship in regards to modulation of RyR2 function, such as JPH2 (Beavers, Wang et al. 
2013, Munro, Jayasinghe et al. 2016). Furthermore, an increase in RyR2 relative to CSQ2 in human 
atrial tissue is observed in AF patients (Voigt, Heijman et al. 2014), and in animal models, a relative 
loss of CSQ2 is associated with AF-like phenotypes (Chopra, Kannankeril et al. 2007, Yeh, Wakili et 
al. 2008, Gergs, Fahrion et al. 2017). My project aimed to investigate if an expression ratio relationship 
exists between RyR2 and CSQ2 in regard to SOICR activity of RyR2, and therefore could 
be a potential mechanism in AF pathogenesis. 
4.1 Initial experiments expressing CSQ2wt with HEK293-RyRwt Cells 
To test the hypothesis of changing RyR2:CSQ2 on Ca2+ leak, we first utilised HEK293-
RyR2wt cells transiently co-expressing CSQ2wt. We aimed to keep the expression of RyR2wt constant 
in each group while changing the expression of CSQ2wt to alter RyR2:CSQ2. To achieve relatively 
consistent expression of RyR2, the exposure of tetracycline (to induce RyR2 expression) was kept to 
an average of 18 hours. To differentially express CSQ2, three experimental groups were transfected 
with different concentrations of CSQ2 cDNA, with a mock transfection group as our control.  
A protocol that kept the concentration of CSQ2wt cDNA transfected constant and instead 
changed the duration of exposure to tetracycline could have been used, but unpublished data from 
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the Jones lab has found that increasing RyR2 expression within HEK293 cells also increases SOICR. 
To avoid this effect of increasing RyR2 expression confounding RyR2:CSQ2’s effect on SOICR, we 
kept RyR2 expression relatively constant and instead changed the CSQ2wt cDNA concentration. 
Although there was a general trend with groups that had increasing CSQ2wt cDNA 
transfection demonstrated a lower percentage of cells exhibiting Ca2+, this result was not consistent 
across all [CaCl2]o and there were no statistically significant differences between groups. Despite the 
lack of statistical significance, the overall trend of increasing CSQ2wt expression while keeping RyR2 
expression relatively constant, and therefore decreased RyR2:CSQ2, is suggestive of a reduced 
propensity for Ca2+ leak, which aligned with my hypothesis and indicated additional investigation 
would be warranted.  
Initially, HEK293 cells expressing both RyR2wt and CSQ2wt were selected to address our 
aim as we wanted to investigate the direct interaction between CSQ2 and RyR2 on Ca2+ leak without 
other cardiac proteins (particularly JNC and TRD) influencing the result. The advantage of HEK293 
cells is that they are derived from embryonic kidney cells, and have been demonstrated to not 
endogenously express these additional cardiac proteins which may otherwise impact RyR2-CSQ2 
interactions (Handhle, Ormonde et al. 2016). Another reason for selecting HEK293 cells as the 
experimental model is the relative ease of altering protein expression levels within the samples. More 
importantly, HEK293 cells stably expressing RyR2 are a well-established model for investigating 
modulators of RyR2 activity (Jiang, Xiao et al. 2004, Waddell, Zhang et al. 2016, Chakraborty, Gonano 
et al. 2019). However, there are a few issues in this initial experimental series that lead to an improved 
approach being established.  
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4.1.1 Issues with Using HEK293-RyRwt and CSQ2wt for my project 
One issue with this approach was the high level of variability in the percentage of cells 
exhibiting Ca2+ leak within groups, particularly with the CSQ2wt cDNA transfected coverslips. There 
are some variables due to using a HEK293 cell model that could explain this variability, including a 
combination of passage differences and an inconsistent transfection efficiency. However, as only cells 
between passages 2-9 were used to reduce the effect of higher passage numbers affecting the 
expression and activity of endogenous proteins being expressed (Luo, Sun et al. 2005, Ponce, Castillo 
et al. 2018), this effect should have been minimised.   
4.1.2 Suggested solutions to the issues with using HEK293-RyRwt and CSQ2wt  
The main problem with Ca2+-phosphate transfection in our HEK293 cells was the large 
variation in T%. The reason Ca2+-phosphate transfection was used was due to its relative ease and 
simplicity, especially when performing multiple transfections at once. While this is a well-established 
method for transfecting HEK293 cells (Jiang, Xiao et al. 2004, Jiang, Jones et al. 2010, Handhle, 
Ormonde et al. 2016), it is possible that it is not optimal for our specific cDNA.  Therefore, it could 
be of interest to investigate whether alternative methods of transfection may be more reliable, such as 
Lipofectamine (Chernousova and Epple 2017).  
Another issue with this original experiment was a lack of a quantifiable measure of protein 
expression. Although we can be reasonably confident that there is a difference in RyR2:CSQ2 between 
groups due to the trend of increasing the concentration of CSQ2wt cDNA transfected on Ca2+ leak, 
we cannot determine RyR2 and CSQ2 expression levels present in each sample. This makes the results 
difficult to compare against other studies in the field. One way to address this lack of quantifiable 
measure of protein expression would be to perform western blotting on cell lysates, similar to 
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Handhle, Ormonde et al. (2016). While this would allow us to see the average amount of RyR2 and 
CSQ2 in each sample group (whole culture lysate) and verify increasing CSQ2 expression with 
transfection, it would still give little indication for RyR2:CSQ2 in individual cells. For this reason, we 
decided to utilise fluorescently tagged RyR2 and CSQ2. Having both RyR2 and CSQ2 fluorescently 
tagged would allow for measuring the fluorescence of each protein to give a relative measure of their 
expression within cells, and express them as a ratio (Section 2.4) to address my hypothesis in 
subsequent experiments. 
4.2 Immunocytochemistry Discussion 
Prior to using the fluorescently tagged CSQ2 in Ca2+ imaging experiments, we needed to 
confirm whether transfected cells that were positive for fluorescence (mCh) were also positive for 
CSQ2. This was assessed using immunocytochemistry as it enabled visualisation mCh fluorescence 
with CSQ2 labelling to verify that these proteins were co-expressed and correctly distributed within 
the cell.  It also enabled us to determine whether CSQ2 was co-localised with RyR2 within the ER. 
4.2.1 CSQ2-N-mCh showed ER Expression and Colocalisation with RyR2 
When looking at our directly linked fluorescent CSQ2 (Fig. 3.4), we found that when cells 
were positive for mCh, they were also positive for CSQ2 labelling. There was also a strong overlap 
for the fluorescence of mCh and CSQ2 labelling, showing that CSQ2-N-mCh cDNA produces CSQ2 
directly linked with the fluorescent tag (mCh). The mCh fluorescence appeared to be localised to the 
ER, which was particularly evident in our live cells (Fig. 3.3 Left).  The overall pattern of mCh 
expression was perinuclear, with a distinct central intracellular region lacking fluorescence which was 
most likely to be the nucleus. This indicated that for CSQ2-N-mCh transfected cells, both CSQ2 and 
mCh expression was distributed to the ER, as expected (Faggioni and Knollmann 2012). We also saw 
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that this CSQ2 and mCh distribution overlapped with the pattern of RyR2 labelling (Fig. 3.4), 
indicating that RyR2 and CSQ2 could be co-localised, as previously demostrateddemonstrated in the 
literature (Handhle, Ormonde et al. 2016).  Importantly, cells which were negative for mCh 
fluorescence were also negative for CSQ2 labelling, supporting previous reports that HEK293 cells 
do not express CSQ2 (Handhle, Ormonde et al. 2016). 
4.2.2 Issues with the CSQ2-N-P2A-mCh Immunohistochemistry 
While positive labelling of directly linked fluorescent CSQ2 (CSQ2-N-mCh) transfected cells 
was obtained (Fig. 3.4), immunocytochemistry of the CSQ2-N-P2A-mCh transfected cells was not 
successful (Fig. 3.5). This was largely due to an apparent loss of cell adherence after fixation. Following 
fixing cells with PFA, there was a large amount of debris in the wells of the 6-well plates where cells 
were prepared indicative of cell detachment. Based on subsequent live-cell imaging, it appears that 
transfected cells tended to lose adherence more readily than non-transfected cells, as we were able to 
identify larger quantities of mCh-positive cells with live cell imaging (Fig. 3.3 and 3.7) when compared 
to our fixed images (Fig. 3.5). One hypothesis regarding cell loss was that the transfection reagents 
reduced the adherence of the cells, leading to the loss of cells after fixation (Section 2.3). To try to 
ameliorate this, the time the cells were exposed to Ca2+-phosphate transfection reagents was reduced 
from 24 hours to 8 hours. Despite altering the protocol, mCh positive cells were still not detected in 
CSQ2-N-P2A-mCh coverslips after fixation. In future, it would be of interest to either increase the 
concentration of poly-L-lysine used to coat the coverslips for improved cell adherence, or to use 
different physiological buffers for the washing steps (such as KRH which is used during Ca2+ imaging), 
to reduce the likelihood of cells detaching. 
Based on the outcome of these experiments, we cannot definitively confirm whether mCh-
positive cells from CSQ2-N-P2A-mCh transfection also expressed CSQ2.  However, considering the 
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presence of mCh-positive cells in live imaging experiments combined with results from the CSQ2-N-
mCh immunocytochemistry, we are reasonably confident that these mCh-positive cells also express 
CSQ2.  In addition, similar to the CSQ2-N-mCh results, there was no CSQ2 labelling identified in 
mCh-negative cells. Despite the inconclusive immunocytochemistry results, given positive 
transfection observed in live cells, it was decided that CSQ2-N-P2A-mCh was the preferred cDNA 
construct for subsequent Ca2+ imaging.  This was due to cleavage of the mCh tag from CSQ2 protein 
(through the use of a P2A linker) which would mitigate the unknown effect of a direct mCh tag on 
CSQ2 function.   
4.3 Tagged CSQ2 Ca2+ imaging 
For these experiments, both our POIs were fluorescently tagged, enable the ratio of mCh:GFP 
fluorescence to be determined (described in section 2.4). This ratio could be used to infer a relative 
ratio of CSQ2:RyR2 (mCh:GFP, respectively). 
4.3.1 Comparison of Controls from Wild-type and Tagged experiments with mCh negative cells 
When the controls (mock transfections) from both our cell lines – HEK293-RyR2wt and 
HEK293-RyR2-GFP – were compared with mCh negative cells (mCh fluorescent signal equal to the 
background), there were no statistically significant differences between the percentage of cells 
exhibiting Ca2+ leak at each [CaCl2]O between groups (Fig. 3.8). This strengthens the conclusion that 
the effects seen in the mCh positive cells were due to changing the mCh:GFP, and not due to 
differences in the cell lines, such as interference from the GFP linked to RyR2. When looking for an 
appropriate CSQ2-null group, mCh negative cells were seen as a possible candidate. It was 
hypothesised that if cells from our CSQ2-N-P2A-CSQ2 coverslips had no mCh fluorescence above 
background signal, then they would also not have CSQ2 present and therefore show a similar 
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percentage of cells exhibiting Ca2+ leak to the other controls. The mCh negative cells exhibited a similar 
percentage of cells exhibiting Ca2+ leak to our other control cells, and were therefore deemed to be an 
appropriate control to use for comparing cells positive for CSQ2 (mCh positive) to cells that were 
CSQ2-null (mCh negative cells).  
 
4.3.2 mCh-positive Cell Analysis Reveals Decreased RyR2:CSQ2 Reduces SOICR 
 When we analysed mCh-positive cells for SOICR activity, we found that as the CSQ2:RyR2 
ratio increased (decreased RyR2:CSQ2), cells exhibited reduced Ca2+ leak. Analysing by this method 
allows us to determine how the propensity for SOICR changes when we increase CSQ2:RyR2. These 
results demonstrate that by increasing CSQ2:RyR2, we reduce the occurrence of SOICR events, in 
agreement with our original hypothesis. 
By only analysing cells that we know are expressing both RyR2 and CSQ2 (GFP and mCh, 
respectively), we are able get a more accurate representation of how these proteins behave together 
within cells. This also overcomes the previous issue in the CSQ2wt experiments with the variability in 
Ca2+-phosphate transfections, as regardless of the T%, we were able to select mCh-positive (CSQ2 
expressing) cells specifically for analysis. This allowed for a more consistent analysis, and resulted in 
reduced variability between experiments, and enabled statistically significant differences to be 
identified.   
4.3.3 Analysis of Ca2+ imaging in mCh positive and negative cells  
While the analysis of mCh-positive only cells enabled specific determination of the effect of 
altering the CSQ2:RyR2 expression ratio, we were also interested in the overall impact of CSQ2 
presence on RyR2 Ca2+ leak.  Therefore, cells that were negative for mCh fluorescence and therefore 
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had no CSQ2 expression, were included in additional analyses with the mCh:GFP groups (Fig. 3.10). 
While not significantly different, an unexpected trend was observed with the mCh negative cells and 
low mCh:GFP group. We expected that they would have more Ca2+ leak than the mCh:GFP cells, to 
match our hypothesis that as we increase CSQ2:RyR2, we will see less SOICR. Interestingly, these 
mCh negative cells had less cells exhibiting Ca2+ leak than our low mCh:GFP group, and a similar 
percentage of cells exhibiting Ca2+ leak as our medium mCh:GFP group..group. Potential explanations 
for this are discussed below (Section 4.4). 
4.3.4 Frequency of SOICR events 
By extending our duration of time exposed to 1 mM CaCl2 (table 2.2), we were able to analyse 
how many SOICR events occurred per minute, known as the FoE (section 2.4). When grouping data 
into the mCh:GFP and mCh negative groups as we did with our previous experiment, overall we 
found that as we increased mCh:GFP (or CSQ2:RyR2), the FoE decreased, in agreement with our 
hypothesis. The result is in agreement with previous reports from Handhle, Ormonde et al. (2016) in 
which cells co-expressing RyR2 and CSQ2 had a lower FoE than cells with just RyR2. However, in 
contrast in this previous study, a biphasic response was not observed between different CSQ2 
treatments and the control group.  In addition to experimental design considerations discussed in 
Section 2.1.3, there are several key differences compared to the study by Handhle, Ormonde et al. 
(2016).  This includes differences between which proteins were stably expressed or transfected, as well 
as different Ca2+ imaging dyes and protocols implemented.  However just like with our previous results 
with the percentage of cells exhibiting Ca2+ leak (Fig. 3.10), our mCh negative cells had a similar FoE 
to the medium mCh:GFP group, and less than the low mCh:GFP group. 
As cells were collected as individual ROIs, it was also possible to show each mCh positive cell 
from the 12 CSQ2-N-P2A-mCh coverslips as an individual value (Fig 3.12). This allowed us to 
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consider each cell’s GFP fluorescence, mCh fluorescence, and mCh:GFP. Analysis of each of these 
variables effect on FoE showed that by decreasing RyR2-GFP expression, or increasing CSQ2-N-
P2A-mCh expression, or mCh:GFP, we observe a reduced FoE. This was done by fitting the plots 
with a line of best fit (linear regression). Although each of these fitted lines were significantly non-
zero, the R2 value for each of these fitted lines were very low. This could suggest that there were 
additional factors other than just CSQ2 or RyR2 affecting FoE in these cells, or that mCh:GFP and 
FoE are not a linear relationship. 
4.3.5 Conclusions for the Tagged Imaging experiments 
When comparing my tagged imaging results to my wild-type imaging results, we can see the 
same trend of decreasing RyR2:CSQ2 leading to decreased SOICR except with significant differences 
identified due to improved accuracy of cell imaging analysis. The significant results of my tagged 
imaging results were also accomplished with less replicates (n of 12 for my tagged imaging, and an n 
of 29 for my wild-type results). This shows that although the hypothesis could have been addressed 
by following the wild-type imaging protocol with more replicates, the tagged imaging protocol was 
more optimal for my hypothesis. 
Through the three different analyses of the tagged imaging experiments, it has been shown 
that in cells that are co-expressing both RyR2 and CSQ2, increasing RyR2:CSQ2 will also decrease the 
[Ca2+] that SOICR occurs at (Fig. 3.9), and increase the frequency of SOICR (FoE) (Figs 3.11 & 3.12). 
However, the [Ca2+] that SOICR occurs at and frequency of SOICR was more severe in high 
RyR2:CSQ2 (low mCh:GFP) than CSQ2-null cells (mCh negative) (Figs.3.10 & 3.11). This shows that 
the effect of RyR2:CSQ2 on SOICR may be biphasic, where a high RyR2:CSQ2 cell may be more 
prone to SOICR than a CSQ2-null cell, but less prone to SOICR than a low RyR2:CSQ2 cell. A 
potential theory for this mechanism is discussed below. 
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4.4 Physiological basis for differences in CSQ2:RyR2’s Biphasic effect on SOICR 
While the primary focus of this project was to examine the ratio effect of CSQ2 and RyR2 
expression on SOICR activity, we were also able to investigate how CSQ2 directly modulates RyR2 in 
the absence of other cardiac accessory proteins. Currently, there are two main theories for how CSQ2 
influences RyR2 directly. 
The first of these theories is that the effect on RyR2 is mediated by the buffering properties 
of CSQ2, which reduces the concentration of free luminal Ca2+ in the SR. This would increase the 
amount of Ca2+ loaded into the SR that is required for a SOICR event to occur. This theory has been 
used to explain how loss of CSQ2 expression in CPVT2 mutations causes a loss of Ca2+ buffering, 
and therefore increases the luminal free Ca2+ (Priori and Chen 2011). However, a well-known effect 
of reduced CSQ2 expression in animal models is an increase in the size of the SR lumen (Knollmann, 
Chopra et al. 2006), which may help to compensate this loss of Ca2+ buffering. The second, more 
recent theory is that CSQ2 can associate directly with RyR2 on its first luminal loop to increase the 
threshold for SOICR (Handhle, Ormonde et al. 2016). The biphasic effect of CSQ2 expression 
observed in the results of this project suggest that both of these theories could be valid.  
4.4.1 Feed-through and CSQ2 
Single channel studies of RyR1 (the skeletal muscle isoform) show that for SOICR to occur, 
two separate sites on RyR must bind Ca2+ (Fig. 4.1) (Laver 2018). The first site is the luminal site (L-
site), which is what is theorised to briefly open the channel when the Ca2+ concentration within the 
SR reach the threshold for SOICR, and cause a  microscopic Ca2+ spark (Jiang, Xiao et al. 2004). This 
microscopic release of Ca2+ then binds to the second site, the activation site (A-site), and sustains the 
opening of the channel (Laver 2007). This theory of SOICR involving the activation of both the L-
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site and the A-site is referred to as the “feed-through” hypothesis of Ca2+ flux from RyR. The A-site 
is typically associated with CICR, and has a higher sensitivity  to Ca2+ than the L-site (Laver 2018). 
When RyR is open, the flux of Ca2+ released into the cytoplasm of cardiomyocytes is dependent on 
the free luminal [Ca2+] within the SR. During CICR, this flux of Ca2+ through RyR needs to be large 
to cause a significant increase in cytoplasmic [Ca2+] (Bers 2002), so the Ca2+ buffering ability of CSQ2 
is proposed to also function to keep the local luminal Ca2+ concentration in the vicinity of RyR high 




Figure 4-1 RyR1 structure reconstructed from cryo-EM images. The red circles show where the 
Ca2+ binding sites are. Ca2+ binds to these sites to cause the opening of the channel. The two sites are the 





Building off the framework provided by Laver (2007), it is possible that the reason cells with 
no CSQ2 present (mCh negative cells) had less SOICR than the low CSQ2:RyR2 cells is due to this 
“feed-through” mechanism and the effect of CSQ2 on local luminal Ca2+. For our cells that did not 
have CSQ2, the lack of the Ca2+ buffering of CSQ2 may have led to a decreased local [Ca2+] near the 
RyR2 channels. This means that if the L-site is activated by luminal Ca2+, it may not have a high enough 
flux of Ca2+ to cause the A-site to be stimulated, meaning we only have the microscopic Ca2+ spark, 
and not the full SOICR event. Cells with no CSQ2 present will still have SOICR events as the free 
luminal [Ca2+] increases, the local [Ca2+] around RyR2 will also increase, and eventually lead to a Ca2+ 
spark flux from L-site stimulation will become large enough to cause A-site stimulation. 
If a low amount of CSQ2 is present, this could increase the local [Ca2+] near RyR2 channels 
through Ca2+ buffering. If the L-site is activated with increased local [Ca2+] present, the Ca2+ spark 
would have a large enough flux to cause the activation of the A-site and sustain the opening of the 
channel, causing a detectable SOICR event in our cells. This could explain the trend that cells with a 
low CSQ2:RyR2 could perhaps paradoxically have more SOICR events at lower [Ca2+] than cells with 
no CSQ2 present, as observed in these results (Fig. 3.10 & 3.11). 
Although we saw more SOICR in our low CSQ2:RyR2 cells than our CSQ2-null cells (mCh 
negative), we also observed less SOICR in our high CSQ2:RyR2 cells than both our low CSQ2:RyR2 
and CSQ2-null cells. One reason for this could be that as CSQ2 expression increases within the SR, 
the effect of CSQ2 on increasing local [Ca2+] becomes saturated and the direct association of CSQ2 
with RyR2 observed in Handhle, Ormonde et al. (2016) becomes more relevant. If RyR2:CSQ2 
decreases to a low enough ratio, then there could be enough CSQ2 present to bind to RyR2 proteins 
to make the initial L-site stimulation less likely, and therefore reduce the amount of SOICR occurring 
despite the local [Ca2+] around RyR2 continuing to increase with more CSQ2 present. This theory of 
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direct association could explain the difference in the amount of SOICR between our low and high 
mCh:GFP groups (Fig. 3.10 & 3.11).  
Although these theories for why there is a biphasic effect on Ca2+ leak are plausible, the current 
results only allow for speculation as to how CSQ2 and RyR2 interact to cause this biphasic effect. 
Further experiments to investigate the role of polymerisation, Ca2+ binding, and effect on feed-through 
Ca2+ flux of CSQ2 would be required to clarify the role of these mechanisms. Nevertheless, the novel 
finding of a biphasic effect on Ca2+ release is very exciting. 
4.5 Implications on AF and Arrhythmia Pathophysiology 
These findings demonstrate that CSQ2 and RyR2 interact in a ratio mechanism, but with an 
apparent biphasic effect where a low CSQ2:RyR2 may have an increased effect on the amount of 
SOICR (Fig. 4.2). These findings indicate that a relative loss of functional CSQ2 expression or relative 
increase of RyR2 expression could increase the severity of SOICR more than originally hypothesised. 
In the context of AF, an increased RyR2:CSQ2 in the atrial cardiomyocytes (Haissaguerre, Jais et al. 
1998) may contribute to the increased arrhythmogenic DADs that have been associated with AF by 
increasing SR Ca2+ leak (Hove-Madsen 2004, Yeh, Wakili et al. 2008). This could also be occurring in 
patients with AF and animal models of AF in which an increased RyR2:CSQ2 is observed (Yeh, Wakili 
et al. 2008, Voigt, Heijman et al. 2014).  By showing that a further decreased RyR2:CSQ2 (or increased 
CSQ2:RyR2) will eventually result in less SOICR, it could be implied that a possible treatment for AF 
could be to target this expression ratio. If a method was available (such as gene editing) that could 
restore a balanced CSQ2:RyR2 expression, then this may have potential therapeutic effect.  Of course, 
RyR2 and CSQ2 are not the only proteins involved in SR Ca2+ leak, so more work would be needed 




Figure 4-2. My original (left) and my new (right) hypothesis of the effect of increasing CSQ2:RyR2 
on SOICR. I originally thought the effect of CSQ2:RyR2 increase would reduce SOICR in a somewhat linear 
mechanism. I found in my results that low CSQ2:RyR2 would cause increased SOICR, and then as 
CSQ2:RyR2 increased further so would SOICR. This indicates a biphasic effect on SOICR when increasing 
CSQ2:RyR2. 
 
4.6 Limitations of the mCh-tagged Ca2+ leak protocol 
As previously discussed, there was considerable variation in T% for the CSQ2-N-P2A-mCh 
cells, which in some instances resulted in relatively few mCh-positive cells (as low as 25 cells). 
Consequently, when they were further split into their three representative mCh:GFP groups there 
could have been as few as 5 cells within a particular mCh:GFP group. These smaller groups are less 
likely to show an accurate representation of how CSQ2:RyR2 affects SOICR, and may impact the 
overall results. 
An advantage of analysing cells for their dose dependence to [Ca2+] is the ability to obtain an 
EC50 value for each group, and have a more quantifiable value for comparison. To calculate the EC50 
for [Ca2+], we need to be able to see the maximum responsiveness to [Ca2+]. For the mCh:GFP cell 
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groups, a maximum response when exposed to 1 mM of CaCl2 was not reached, and therefore the 
EC50 for their response to [Ca2+] could not be determined. While previous studies using this 
HEK293-RyR2 cell model have previously demonstrated a maximum response (Jiang, Xiao et al. 2004, 
Jiang, Wang et al. 2005), it is suspected that due to the Ca2+ buffering properties of CSQ2 (Wang and 
Michalak 2020), it may take a much higher [Ca2+] to see a maximal response.  
4.7 Conclusion 
Based upon the data I have collected, the use of fluorescently tagged CSQ2 and RyR2 in single-
cell Ca2+ imaging is a viable and valuable method for assessing the Ca2+ leak associated with changing 
RyR2 and CSQ2, and is a significant improvement on the use of CSQ2wt and RyR2wt. My initial 
hypothesis of “as the RyR2:CSQ2 is decreased we will see less SOICR overall” was for the most part true.  
The caveat to this is the novel finding of a biphasic effect of low CSQ2:RyR2 trending to increase 
SOICR activity. I speculate this biphasic effect may be due to both the “feed-through” hypothesis for 
Ca2+ release (Laver 2007) and the direct physical association of RyR2 and CSQ2 (Handhle, Ormonde 
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Table 6-1 p values of repeated measures 2-way ANOVA of data within Figure 3-9. Significant 





Low vs Med Low vs High Med vs High 
0 ND ND ND 
0.1 0.3391 0.5394 0.7675 
0.2 0.1139 0.0340 0.5099 
fin0.3 0.3295 0.0096 0.0264 
0.5 0.2089 0.0121 0.2178 
1.0 0.2166 0.0288 0.4123 
 
Table 6-2 p values of repeated measures 2-way ANOVA of data within Figure 3-10. Significant 























0 ND ND ND ND ND ND 
0.1 0.4859 0.7053 0.9037 0.8970 0.5799 0.6543 
0.2 0.1836 0.0583 0.9779 0.6791 0.0667 0.0325 
0.3 0.4762 0.0172 >0.9999 0.0465 0.0517 <0.0001 
0.5 0.3214 0.0218 0.8890 0.3343 0.3521 0.008 
1.0 0.3317 0.0499 0.2590 0.5745 0.9913 0.3520 
 
